Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. Zhu, MH., Liu, ZJ., Hu, QY., Yang, JY., Jin, Y. & Zhu, N. et al. Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial. Mil. Med. Res. 9, 59 (2022).
2. Geyer, M. A., Olivier, B., Joels, M. & Kahn, R. S. From antipsychotic to anti-schizophrenia drugs: role of animal models. Trends Pharmacol. Sci. 33, 515–521 (2012).
3. Young, J. W. & Geyer, M. A. Developing treatments for cognitive deficits in schizophrenia: the challenge of translation. J. Psychopharmacol. 29, 178–196 (2015).
4. Green, M. F., Kern, R. S., Braff, D. L. & Mintz, J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr. Bull. 26, 119–136 (2000).
5. Furth, K. E., Mastwal, S., Wang, K. H., Buonanno, A. & Vullhorst, D. Dopamine, cognitive function, and gamma oscillations: role of D4 receptors. Front. Cell Neurosci. 7, 102 (2013).